Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting. (IDCaPP)

Kelley-Ross & Associates

Status: Completed

Conditions: HIV Infections

Treatments: Drug: Cabotegravir Injection [Apretude]

Study type: Observational

Funder types: Other

Identifiers

NCT05867212

001

Details and patient eligibility

About

The goal of this demonstration project or observational study is to evaluate the feasibility and acceptability of a pharmacist-managed cabotegravir long acting injectable for PrEP program in a community pharmacy setting.

The main question it aims to answer are:

• Is the program feasible and acceptable at the end of 1 year of operations?
• What are the facilitators and barriers of the program? Participants who want to start the FDA approved cabotegravir long acting injectable medication for PrEP will have the option participating in surveys and a review of their electronic health records. Medication will be administered based on FDA approved labeling guidelines and their PrEP care will be part of standard of care per CDC.

Pharmacists who want to provide the service to their patients will have the option of participating in surveys pre and post implementation.

Enrollment: 50 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• 18 years of age or older at the time of screening
• Weight ≥ 35 kg
• HIV-negative status
• Willing to provide informed consent and undergo all required study procedures.

Exclusion criteria

• Unknown or positive HIV status
• Coadministration of drugs that significantly decrease cabotegravir concentrations according to the FDA package insert.
• Any participants that do not meet criteria for management under CDTA